ArticleBiometrics2025
A semicompeting risks model with an application to UK Biobank data to identify risk factors for diabetes onset and progression.
Article in Biometrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Type 2 diabetes (T2D) is a major health concern worldwide with multiple disease stages, including onset, progression to complications, and death. Understanding the roles of genetic and nongenetic factors at different disease stages is crucial for gaining insights into disease etiology, possible prevention, and treatment strategies. The UK Biobank (UKB) is a valuable resource for studying complex diseases, including T2D, with comprehensive data from half a million volunteer participants. However, the UKB data present some unique challenges due to their semicompeting risks structure, involving 2 nonterminal events (T2D and complications) and one terminal event (death). In this paper, we propose a new shared gamma frailty-based semicompeting risks model within the Bayesian framework to account for subsequent nonterminal and terminal events and enable appropriate analysis. We further propose incorporating prevalent cases, that is, individuals with diabetes at enrollment, to gain more insights into the progression to complications and complications to death. To integrate prevalent cases, we introduce a power prior approach that leads to improved model fit and more efficient estimates. Simulation results demonstrate the efficacy of our modeling framework. We apply our method to identify the impacts of various risk factors at different stages of T2D development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.